In recent years, big pharma has talked about the patent cliff and strategies to address lost revenues as blockbuster drugs went off-patent in the U.S. and Europe. But with the turn of the calendar page, 2013 means a change in circumstances – while big pharma still needs to build up portfolios and pipelines to recover from the patent cliff, the worst is over for now, while generic drug companies must strategize for an environment providing fewer big-ticket 180-day exclusivity opportunities.
In the U.S., relatively few exclusive and Paragraph IV opportunities will be present in 2013. The value of drugs going...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?